» Articles » PMID: 11559562

On the Site and Mode of Antigen Presentation for the Initiation of Clonal Expansion of CD8 T Cells Specific for a Natural Tumor Antigen

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Sep 18
PMID 11559562
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Because of the low frequency of antigen-specific T cells, early events in the activation of tumor-specific T cells in vivo have not been well characterized. There is still no direct documentation on where the clonal expansion begins and how tumor antigens are presented to the host CD8 T cells to initiate it. Here we used transgenic T cells specific for a natural tumor antigen P1A to evaluate the kinetics, location, and modes of antigen presentation for initiating CTL response in vivo. Our results demonstrate that the initial activation of P1A-specific T cells takes place in the lymphoid organs. The activated T cells then migrate into tumors, where they undergo accelerated division and acquire distinct activation markers. The site of initiation cannot be altered by either local expression of costimulatory molecules or by intratumor injection of naïve T cells. Moreover, using genetic models that allow only one mode of antigen presentation, we show here that both cross-presentation of P1A by the host antigen-presenting cells, and direct antigen presentation and costimulation by the tumor cells are sufficient to initiate rapid T cell-clonal expansion in the lymphoid organ. These results provide direct evidence for two fundamental assumptions on the mechanisms of T-cell activation in vivo.

Citing Articles

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor Microenvironment.

Zhu J, Yu J, Hu A, Liu J, Pan X, Xin G J Immunol. 2023; 211(5):895-902.

PMID: 37459051 PMC: 10530257. DOI: 10.4049/jimmunol.2300176.


Dendritic cell expression of CD24 contributes to optimal priming of T lymphocytes in lymph nodes.

Zhang X, Yu C, Liu J, Bai X Front Immunol. 2023; 14:1116749.

PMID: 36969215 PMC: 10033833. DOI: 10.3389/fimmu.2023.1116749.


Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?.

Li B Front Immunol. 2022; 13:973881.

PMID: 36341370 PMC: 9635507. DOI: 10.3389/fimmu.2022.973881.


CD4 and CD8a PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Kristensen L, Frohlich C, Christensen C, Melander M, Poulsen T, Galler G Theranostics. 2019; 9(26):8221-8238.

PMID: 31754392 PMC: 6857046. DOI: 10.7150/thno.37513.


Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.

Patel J, Cui Z, Wen Z, Dinh C, Hu H J Immunother Cancer. 2019; 7(1):311.

PMID: 31747946 PMC: 6865022. DOI: 10.1186/s40425-019-0786-7.